BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 37143942)

  • 1. Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang S; Qiu C; Yu H; Xu Y; Xu X
    Front Oncol; 2023; 13():1070019. PubMed ID: 37143942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Li LL; Pan LS
    Kaohsiung J Med Sci; 2023 Aug; 39(8):842-852. PubMed ID: 37166079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen X; Meng F; Jiang R
    Front Oncol; 2021; 11():746976. PubMed ID: 34900692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis.
    Tan Q; Liu S; Liang C; Han X; Shi Y
    Thorac Cancer; 2018 Oct; 9(10):1220-1230. PubMed ID: 30151899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: a systematic review and meta-analysis.
    Matsas S; Aguiar PN; Del Giglio A
    J Gastrointest Oncol; 2024 Feb; 15(1):33-51. PubMed ID: 38482212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.
    Sacdalan DB; Lucero JA; Sacdalan DL
    Onco Targets Ther; 2018; 11():955-965. PubMed ID: 29503570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
    Front Oncol; 2022; 12():795933. PubMed ID: 35223476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
    Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
    BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review.
    Guo Y; Xiang D; Wan J; Yang L; Zheng C
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis.
    Zhou K; Cao J; Lin H; Liang L; Shen Z; Wang L; Peng Z; Mei J
    Front Oncol; 2022; 12():962173. PubMed ID: 36059629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
    Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
    Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta-analysis.
    Leng J; Wu F; Zhang L
    Front Oncol; 2022; 12():734948. PubMed ID: 35651788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Rugambwa TK; Abdihamid O; Zhang X; Peng Y; Cai C; Shen H; Zeng S; Qiu W
    Front Oncol; 2023; 13():1181248. PubMed ID: 38023176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Li S; Wang T; Tong G; Li X; You D; Cong M
    Front Oncol; 2021; 11():726257. PubMed ID: 34513704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis.
    Jin J; Yang L; Liu D; Li W
    BMJ Open; 2020 Jun; 10(6):e035031. PubMed ID: 32499266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang Y; Liu B; Kotenko S; Li W
    Medicine (Baltimore); 2022 Aug; 101(32):e29536. PubMed ID: 35960066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of prognostic nutritional index inĀ advanced cancer receiving PD-1/L1 inhibitors: A meta-analysis.
    Li P; Lai Y; Tian L; Zhou Q
    Cancer Med; 2022 Aug; 11(16):3048-3056. PubMed ID: 35297197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.